The price-to-earnings ratio for Abbott Laboratories (NYSE: ABT) is above average at 33.39x, Company’s 36-month beta value is 0.75.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ABT is 1.72B, and currently, short sellers hold a 0.84% ratio of that floaft. The average trading volume of ABT on April 22, 2024 was 5.88M shares.
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT) has experienced a rise in its stock price by 1.91 compared to its previous closing price of 105.27. However, the company has seen a fall of -1.68% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-20 that Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareholder returns. Blending higher-yielding dividend stocks with those offering growth potential creates a balanced approach suitable for most investors.
ABT’s Market Performance
ABT’s stock has fallen by -1.68% in the past week, with a monthly drop of -3.78% and a quarterly drop of -6.46%. The volatility ratio for the week is 2.58% while the volatility levels for the last 30 days are 1.73% for Abbott Laboratories The simple moving average for the last 20 days is -2.98% for ABT’s stock, with a simple moving average of 0.55% for the last 200 days.
Analysts’ Opinion of ABT
Morgan Stanley, on the other hand, stated in their research note that they expect to see ABT reach a price target of $112. The rating they have provided for ABT stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Wolfe Research gave a rating of “Underperform” to ABT, setting the target price at $103 in the report published on April 20th of the previous year.
ABT Trading at -6.11% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.81% of loss for the given period.
Volatility was left at 1.73%, however, over the last 30 days, the volatility rate increased by 2.58%, as shares sank -3.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.32% lower at present.
During the last 5 trading sessions, ABT fell by -1.68%, which changed the moving average for the period of 200-days by -0.08% in comparison to the 20-day moving average, which settled at $110.36. In addition, Abbott Laboratories saw -2.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Salvadori Daniel Gesua Sive, who sale 963 shares at the price of $118.50 back on Mar 01 ’24. After this action, Salvadori Daniel Gesua Sive now owns 125,697 shares of Abbott Laboratories, valued at $114,116 using the latest closing price.
ALLEN HUBERT L, the EXECUTIVE VICE PRESIDENT of Abbott Laboratories, sale 853 shares at $118.50 during a trade that took place back on Mar 01 ’24, which means that ALLEN HUBERT L is holding 184,806 shares at $101,080 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.54 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.11. Equity return is now at value 15.15, with 7.72 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.49. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 10.86.
Currently, EBITDA for the company is 10.59 billion with net debt to EBITDA at 0.98. When we switch over and look at the enterprise to sales, we see a ratio of 4.84. The receivables turnover for the company is 6.14for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In a nutshell, Abbott Laboratories (ABT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
